

Cv Messouadi

(DEA, **2001**) under the supervision of Prof. Pascale Moreau at Blaise Pascal University (Clermont Ferrand, France) and PhD in **2004** in the group of Prof. **Michelle Prudhomme** (SEESIB, UMR 6296, Clermont Ferrand) working on the synthesis of Rebecamycine, Staurosporine and Granulatimide analogues as anticancer agents. He then worked as a post-doctoral fellow with Prof. **David. J. Aitken** in the total synthesis of Microsclerodermin C. Following a second post-doctoral fellowship (Dr. Mouad Alami/ Prof. J.-D. Brion) at the Pharmacy Faculty of Châtenay Malabry (Paris Sud University), he was appointed CNRS Researcher (**2007**) and joined the group of "Therapeutic Chemistry" at the University of Paris 11. He obtained his Habilitation diploma (HDR) in January **2011**, working mainly on the transition-metal catalyzed C-C and C-heteroatom bond forming methodologies, Diversity-Oriented Synthesis (DOS) in sugars and heterocycles, as well as the preparation of molecules and molecular scaffolds of biological and therapeutic interest (Hsp90 inhibitors and vascular disrupting agents). Promoted as a "Directeur de Recherche" (DR2) in **2017**.

Member of the CoNRS (Comité National CNRS, Section 16, INC) for the period 2012-2016.

He was the recipient of the "Prix d'Encouragement à la Recherche en Chimie Thérapeutique" award of the French Therapeutic Chemistry Society and SERVIER laboratories in 2012.

Co-authors of 70 publications and 5 patents.